Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344545 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4585397 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL9013118 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4584429 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4586718 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4585040 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4585106 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL4584095 | 1.00 | TDP1 (0.44) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL239455 | 0.98 | TDP1 (0.46) | TDP1L3MBTL1KCNH2LIPGTRPV1 | |
| SCHEMBL695229 | 0.92 | L3MBTL1 (0.39) | TDP1L3MBTL1KCNH2TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334391-B2 | Functionalized heteroacenes | XEROX CORPORATION (US) | 2012-12-18 | — | — | US | claimed |
| US-7372071-B2 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20070260069-A1 | Functionalized heteroacenes | XEROX CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070235721-A1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION | 2007-10-11 | — | — | US | claimed |
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3401310-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086525-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| EP-1843410-B1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORP (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1843410-A2 | Functionalized heteroacenes and electronic devices generated therefrom | Xerox Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060293503-A1 | Polyaminopyridines and method for producing same | SUMITOMO SEIKA CHEMICALS CO., LTD (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | TDP1 1258/4885L3MBTL1 2507/4885KCNH2 4161/4885 |
| US-20070260069-A1 | Functionalized heteroacenes | SOD1, AHR, NR0B2 | TDP1 3945/4885L3MBTL1 1684/4885KCNH2 1459/4885 |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | PNLIP, PLIN1, HDAC11 | TDP1 1874/4885L3MBTL1 620/4885KCNH2 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.